This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Massimo, L. Articles by Grossman, M. Search for Related Content PubMed PubMed Citation Articles by Massimo, L. Articles by Grossman, M. Social Bookmarking                         What's this?

Patient Care and Management of Frontotemporal Lobar Degeneration

Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania, massimol{at}uphs.upenn.edu

Murray Grossman, MD

Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania

Frontotemporal lobar degeneration (FTLD) is a neurodegenerative disease that affects frontal and temporal regions of the brain. Two proteins indicated in the pathology are tau and the recently discovered TDP-43. Major manifestations include progressive aphasia and a disorder of social comportment. The diagnosis of a patient includes a detailed cognitive exam, clinical testing, and neuroimaging techniques. The current goal of therapy for FTLD is symptomatic management with medications borrowed from other conditions. Nonpharmacologic management such as behavioral interventions and environmental engineering are also efficacious in optimizing quality of life.

Key Words: frontotemporal lobar degeneration • TDP-43 • symptomatic management • nonpharmacologic management

American Journal of Alzheimer's Disease and Other Dementias®, Vol. 23, No. 2, 125-131 (2008)
DOI: 10.1177/1533317507307961


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?